Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to -$3.6 million.

  • Ligand Pharmaceuticals' Change in Inventory fell 8576.6% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.8 million, marking a year-over-year increase of 3840.21%. This contributed to the annual value of -$9.6 million for FY2024, which is 18849.13% down from last year.
  • Ligand Pharmaceuticals' Change in Inventory amounted to -$3.6 million in Q3 2025, which was down 8576.6% from $875000.0 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Change in Inventory's 5-year high stood at $13.0 million during Q2 2023, with a 5-year trough of -$9.7 million in Q2 2022.
  • Moreover, its 5-year median value for Change in Inventory was -$1.4 million (2022), whereas its average is -$662842.1.
  • In the last 5 years, Ligand Pharmaceuticals' Change in Inventory surged by 87298.16% in 2021 and then plummeted by 452500.0% in 2023.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Change in Inventory stood at -$2.7 million in 2021, then skyrocketed by 49.33% to -$1.4 million in 2022, then soared by 47.86% to -$707000.0 in 2023, then plummeted by 262.94% to -$2.6 million in 2024, then plummeted by 39.87% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, $875000.0 for Q2 2025, and $500000.0 during Q1 2025.